Get the Stockscreener App
1.78
3.49%
0.06
After Hours:
1.79
0.01
+0.56%
Unity Biotechnology Inc stock is traded at $1.78, with a volume of 251.40K.
It is up +3.49% in the last 24 hours and down -8.25% over the past month.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$1.72
Open:
$1.73
24h Volume:
251.40K
Relative Volume:
1.08
Market Cap:
$29.99M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.4863
EPS:
-3.66
Net Cash Flow:
$-39.93M
1W Performance:
+4.71%
1M Performance:
-8.25%
6M Performance:
+27.14%
1Y Performance:
+14.84%
1-Day Range:
$1.73
$1.98
1-Week Range:
$1.53
$1.98
52-Week Range:
$0.9397
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Name
Unity Biotechnology Inc
Sector
Industry
Phone
(650) 416-1192
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Compare UBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.78 | 29.99M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-16-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-04-22 | Upgrade | ROTH Capital | Neutral → Buy |
| Nov-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Jun-28-21 | Upgrade | Citigroup | Sell → Buy |
| Jun-07-21 | Initiated | H.C. Wainwright | Buy |
| Feb-16-21 | Downgrade | Citigroup | Neutral → Sell |
| Aug-18-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-18-20 | Downgrade | Mizuho | Buy → Neutral |
| Aug-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-17-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-28-20 | Initiated | ROTH Capital | Buy |
| Dec-12-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Initiated | Mizuho | Buy |
| May-29-18 | Initiated | Citigroup | Buy |
| May-29-18 | Initiated | Goldman | Neutral |
| May-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Unity Biotechnology Inc Stock (UBX) Latest News
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks
UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors - StockTitan
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks
Unity Biotechnology Reports 2024 Financial Results and Updates - TipRanks
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks
UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-K Report - TradingView
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire
Korro Bio CFO takes medical leave, interim officers appointed - Investing.com
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431 - MSN
Unity Biotechnology CFO sells shares worth $341 - Investing.com India
Unity Biotechnology CFO sells shares worth $341 By Investing.com - Investing.com Nigeria
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431 By Investing.com - Investing.com Nigeria
Senolytic Drugs Market is expected to reach a revenue of - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
UBX stock touches 52-week high at $2.02 amid market optimism - MSN
Adversity is less terrifying than hope: Unity Biotechnology Inc (UBX) - SETE News
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan - TechCrunch
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - PR Newswire UK
UBX stock touches 52-week high at $2.02 amid market optimism By Investing.com - Investing.com South Africa
Empery Asset Management, LP Increases Stake in Sobr Safe Inc - GuruFocus.com
Research Analysts Offer Predictions for UBX FY2024 Earnings - Defense World
Geode Capital Management LLC Buys 14,199 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Unity Biotechnology (NASDAQ:UBX) Coverage Initiated at Chardan Capital - Defense World
Chardan initiates Unity Biotechnology stock with Buy rating, cites senolytic UBX1325 potential - Investing.com India
UBXUnity Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Unity Biotechnology (NASDAQ:UBX) Shares Down 26.5% – Here’s What Happened - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
UNITY Biotechnology Reports Granting of New Employment Inducement Award - GlobeNewswire
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
UNITY Biotech appoints new chief medical officer - Investing.com
UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO Ahead of Key DME Trial Results - StockTitan
Unity Biotechnology Names Federico Grossi Chief Medical Officer, Pre-market Stock Rises - Nasdaq
Unity Biotechnology, Inc. (NASDAQ:UBX): Is Breakeven Near? - Simply Wall St
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate - Yahoo Finance
Ten Levels of Longevity: #5 aging disease management - Longevity.Technology
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com India
Unity Biotechnology stock hits 52-week low at $0.95 By Investing.com - Investing.com Nigeria
Unity Biotechnology stock hits 52-week low at $0.95 - Investing.com
Unity Biotechnology (NASDAQ:UBX) Trading Down 5.6% – What’s Next? - Defense World
Unity Biotechnology stock hits 52-week low at $1.1 - Investing.com
Unity Biotechnology Inc Stock (UBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):